Abemaciclib CAS NO.1231929-97-7

Anhui Haikang Pharmaceutical Co.,
Ltd. is a collection of scientific
research,production and sales
High-Tech Enterprise,which
established in 2009,and covers an
area of 28,000 ㎡.Company locates
in Anqing city,on the bond of
Yangtze River, invested 80 million
RMB to set up synthesis workshops
and clean workshops.All the
productions strictly conform to GMP
standard and equipped with
high-class R&D center.The first
branch was founded in 2010,called
Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Abexicil is an oral cyclin-dependent kinase CDK4/6 inhibitor. In HR+, HER2- breast cancer cells, CDK4 and CDK6 can promote the phosphorylation of retinoblastomap Chemicalbookrotein (Rb) and promote Cell cycle progression and cell proliferation. Abemaciclib can inhibit the phosphorylation of Rb and block the progression of cells from the G1 phase to the S phase of the cell cycle, leading to cell senescence and apoptosis.

The approval of Abemaciclib is based on the results of the pivotal phase III clinical study MONARCHplus. MONARCHplus is a randomized, double-blind, phase III clinical trial focusing on Chinese women with HR+/HER2-postmenopausal advanced breast cancer. In the study, 306 patients received abexiride or placebo combined with aromatase inhibitors (letrozole or anastrozole) as initial endocrine therapy (cohort A), and 157 patients who progressed after endocrine therapy received abexiride or Placebo combined with fulvestrant treatment (cohort B). The results of the interim analysis were announced at the 2019 European Society of Medical Oncology (ESMO) annual meeting. The study reached the primary endpoint: In cohort A, compared with placebo, the median PFS of the abecili combination group was significantly higher than that of the control group. Chemicalbook Prolonged, the median PFS has not yet been reached in the abecili combination group, and the non-steroidal aromatase inhibitor (NSAI) single-agent group has reached 14.73 months (HR0.499, P=0.001). In cohort B, the median PFS of the combination group of abexiride was significantly longer than that of the fulvestrant monotherapy group, which was 11.47 vs 5.59 months (HR 0.376, P <0.001) as an oral CDK4/6 inhibitor Abexicil is the only single drug approved for endocrine therapy and metastatic patients after previous chemotherapy treatments have progressed. In addition, endocrine therapy combined with CDK4/6 inhibitors has become the standard treatment plan for HR+/HER2-mBC patients. The approval of Abexicil means that domestic breast cancer patients are ushered in more treatment options, and it also brings more new treatment possibilities.